News
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
Source: Fierce Biotech Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront. The prize for Jazz is Actio’s lead asset, dubbed ABS-1230, a small-molecule precision therapy targeting…
AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect
Source: Fierce Biotech AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi. Apogee’s lead candidate is zumilokibart,…
Jazz hands over $935M to buy Chimerix for near-approval cancer drug
Source: Fierce Biotech Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will give Jazz control of the brain cancer drug…
FDA blesses atopic dermatitis label expansions for Organon’s Vtama, Galderma’s Nemluvio
Source: FiercePharma The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger patient population as roughly 26 million in the U.S. have…
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Source: FiercePharma With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion,…
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation…
LEO Pharma to Acquire Timber Pharmaceuticals
Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of…
Rick Beck – Founding Recruiter on Forbes.jobs
Meet Rick Beck, a highly respected executive recruiter with a passion for connecting top talent with leading companies in the pharmaceutical, medical device, and biotechnology industries. With a nationwide reach, Rick and his team use a unique 48-point assessment…
L’Oreal to acquire skinbetter science
Clichy, September 23, 2022 – L’Oréal signed an agreement to acquire Skinbetter Science, a physician-dispensed American skincare brand backed by cutting-edge, dermatological science, combining patented efficacious ingredients with luxurious sensorial textures….
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company
Source: EPI Health The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN). Novan will host a conference call and webcast, today, March…
HAVE A QUESTION?
We are here to help. Email us or call 480.907.7690